If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
A German company active in the field of biotechnology developed a rapid and reliable characterisation of epitopes at the level of single amino acids and their allowed variations. The method identifies up to thousands of potential epitope/mimotope peptides combining even structural epitopes in single peptides to predict species specificity and fitness for usage. Only µg amounts of antibody are required. The company is looking for partners for research or technical cooperation agreement.
A young German company, founded in 2016, is specialised in the field of antigen recognition.
The founder developed a method for the rapid and reliable characterisation of epitopes at the level of single amino acids and their allowed variations. The method identifies up to thousands of potential epitope/mimotope peptides combining even structural epitopes in single peptides to predict species specificity and fitness for usage. Only µg amounts of antibody are required.
The technique has been applied to identify more than 1,000 epitopes often followed up by synthesis and binding tests with peptides.
The company is looking for partners from R&D or industry for further development under research or technical cooperation agreement.
A single experiment with a few µg antibodies and a standardized peptide library on phage particles generates thousands of binding sequences in a pool of a million unspecific binders. The innovation is to identify the binders by statistical means and to calculate potential variations of the recognized epitope. The large number of binders identified allows also to select peptides for multiple applications, e.g. purification, competitors with different affinities or (recombinant) antibody QC.
Standard epitope mapping is usually based on single peptide measurements or large-scale mutagenesis of the antigen. The disadvantage is that either the peptides or the protein must be synthesized or available by expression, which generates costs and requires a new set up for every antibody and limits their usage for difficult antigens. This service requires
- no antigen
- minute amounts of (unpurified) antibody
- only a few weeks for processing
The LibDB software required for the data evaluation is a specially designed tool to handle statistical analyses of phage display experiments with our libraries.
There are partners sought from industry or R&D institutions with Know-how in recombinant antibody diagnostics or therapy for further research or further technical improvement or to develop further applications for specific needs.